July 21, 2022
Studies On Adaptive Trials In Rare Cancer
Rare cancers account for up to 20% of new cancer cases and Innovative Medicinal Products (InMP) are required to address this high unmet medical need. Adaptive trials may be an alternative to large randomized controlled trials for InMP development to target rare cancer patients.
Our research with KOLs & HCPs have helped inform studies about the perceived value of adaptive trials and surrogate endpoints for clinical decisions. Oncologists rated evidence from adaptive clinical trials with as a high value and importance for clinical decision processes as randomised controlled trials. The results have been presented at ASCO, ESMO, and published in Frontiers In Oncology.
If you are unable to access the abstract, please do contact us for a summary.